Evidence Snapshot

Fibroblast growth factor receptor

CHEMBL2095217 PROTEIN FAMILY Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T10:04:59Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 13, 2026, 7:04 PM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL2095217

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Fibroblast growth factor receptor as ChEMBL target CHEMBL2095217, mapped to UniProt P22607. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Fibroblast growth factor receptor

PROTEIN FAMILY · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL2095217

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

P22607

Fibroblast growth factor receptor 3

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Fibroblast growth factor receptor matters

As of 2026-09-13

Fibroblast growth factor receptor is reviewed as Fibroblast growth factor receptor 3 (UniProt P22607); Fibroblast growth factor receptor shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block.; 11 linked drugs keep this evidence frame grounded.; the current evidence base includes 2 approved drugs, 279 compounds, and 115 assays, with lead potency reaching pChEMBL 9.4.

Protein context

Fibroblast growth factor receptor 3

Fibroblast growth factor receptor 3 Sequence length is 806 aa.

Review this target as Fibroblast growth factor receptor, mapped to UniProt P22607. ChEMBL maps the protein component as Fibroblast growth factor receptor 3. Sequence length is 806 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P22607 Protein

Disease context

neoplasm

Fibroblast growth factor receptor shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 11 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include BRIVANIB, BRIVANIB ALANINATE, DERAZANTINIB.

Start review with neoplasm because it currently carries approved-linked support. Linked drugs include BRIVANIB, BRIVANIB ALANINATE, DERAZANTINIB, ENMD-981693. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Approved-linked 11 linked drugs

Activity base

Portfolio and assay base

ChEMBL currently tracks 2 approved drugs, 279 compounds, and 115 assays for this target. The dominant activity type is IC50. CHEMBL190161 is the current potency anchor at pChEMBL 9.4.

Use CHEMBL190161 as the tractability anchor when discussing potency (pChEMBL 9.4).

Activity source · ChEMBL 36 via Core Engine

2 approved pChEMBL 9.4

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Fibroblast growth factor receptor matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P22607, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why neoplasm is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

279

Total Compounds

115

Total Assays

Approved Drugs

IC50: 287.0, KI: 10.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL190161	9.4	IC50	—
No preferred name CHEMBL191023	9.3	IC50	—
No preferred name CHEMBL191070	9.3	IC50	—
No preferred name CHEMBL339856	9.0	IC50	—
No preferred name CHEMBL189995	9.0	IC50	—